AstraZeneca, Daiichi Sankyo partner with Summit on cancer trial
The core of this positive news is AstraZeneca and Daiichi Sankyo's partnership with Summit for cancer clinical trials.
The current price of $16.69 is situated between the 20-day support line ($15.18) and resistance line ($19.09). As moving averages are unaligned in a bearish phase, a phased approach near the support line is deemed advantageous, leading to the consideration of a purchase.
Since the moving averages are not aligned and the market is in a bearish phase, cut losses if the 20-day support level of $15.18 is broken, and conversely, take profits if the upward trend continues and reaches the resistance level of $19.09.
At the entry point, the technical indicators are confirmed as follows: RSI (14) at 43.9, moving averages out of alignment (non-bullish arrangement), trading volume at 1.03 times the 20-day average, and a -2.5% volatility rate over the past 7 days.
Among past successful cases, the SMMT case, which recorded a 28.2% return on 2026-09-04, is similar to the current partnership news flow in that the keyword "AstraZeneca" overlaps. Other cases, VEEE (451.7%) and LRCX (346.8%), have no basis for direct similarity but are included for reference as top-performing cases globally.
We entered the position expecting a rebound near the 20-day support level ($15.18), backed by the heavy positive catalyst of AstraZeneca and Daiichi Sankyo's cancer clinical partnership. However, the actual outcome resulted in a -12.3% loss, earning a FAILED rating. The miscalculation stemmed from relying solely on the potential impact of the news, overlooking the bearish context at entry—namely, an RSI (14) of 43.9 and a non-aligned moving average structure—alongside a lack of meaningful volume explosion (1.03x the 20-day average) and ongoing downward pressure reflected in a -2.5% stock price change over the preceding 7 days.
Through this failed trade, we confirmed that no matter how significant the partnership catalysts are in major pharmaceutical and biotech themes (such as AstraZeneca-related news), downward pressure can outweigh support in a bearish phase where moving averages have not yet formed a bullish alignment, provided support levels fail to hold firmly. Going forward, we will exercise utmost diligence in risk management by strictly evaluating not only macro indicators such as theme news trends and the S-Class conversion rate (15.9%), but also non-bullish alignments on technical indicators and the inflow of trading volume.